- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Michael Burke, Ovation
S
Michael Burke
Chief Commercial Officer, Ovation
SPECIALIZES IN: "Creative solutions" to product strategy
ROLE MODELS: "Can do good and do well at the same time"
Doing deals is fun," says Michael Burke, who's helped build Ovation from "a couple people in a room to 350 employees, 20 products, and four development programs." Executing CEO Jeff Aronin's strategy of acquiring and relaunching Big Pharma drugs in underserved market segments, Burke has become expert in prudent risk—the industry's holy grail.
Michael Burke
Training in what he calls creative solutions primed him for setting the commercial agenda at Ovation, where innovation barely describes the new forms of life he and Aronin have discovered in acquiring, partnering, and marketing their Big Pharma ugly ducklings. Burke has had the most fun with Sabril, which prior to Ovation sat at FDA "with an open Approvable Letter longer than any other product in history." But by collaborating with academics and advocates, Ovation filed a new NDA for infantile spasms, a condition with high unmet need.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
